$BDRX

Biodexa Pharmaceuticals (BDRX) CEO Stephen Stamp discussed the company's lead drug candidate, eRapa, for treating Familial Adenomatous Polyposis (FAP). The Phase 3 trial, Serenta, is over 50% enrolled with interim data expected in Q1 2027. eRapa aims to reduce surgical interventions, and the company has received $20M in grant funding. Biodexa claims a development lead over competitors, with a focus on safety and convenience.

RH (NYSE:RH) shares rose 8.2% in pre-market trading after reporting Q2 earnings of $2.70 per share, beating estimates by 51.69%. Revenue was $922.15M, up from last year but below expectations. Other movers included Oracle (NYSE:ORCL), Alliance Entertainment (NASDAQ:AENT), and ACV Auctions (NYSE:ACVA).

Biodexa Pharmaceuticals (BDRX) has enrolled 87 of 168 planned patients in its Phase 3 Serenta trial for eRapa in Familial Adenomatous Polyposis (FAP), with sites in the U.S. and Europe. The trial aims to evaluate eRapa, a rapamycin-based treatment, with a $20M grant supporting the program. BDRX stock is up 6.62% to $23.82.

Biodexa Pharmaceuticals PLC has issued a letter to shareholders detailing proposals to reorganize the company’s share capital at the upcoming Annual General Meeting. These proposals aim to rationalize the share capital by reducing the number of ordinary shares without affecting shareholders' rights, percentage ownership, or the number of American Depositary Shares (ADSs) outstanding. The changes involve a reverse split, subdivision, redesignation of shares, and an adjustment to the ordinary share/ADS ratio, all recommended by the Board.

Biodexa Pharmaceuticals plans a significant capital reorganization at its June 17, 2026 AGM, including a 10,000:1 reverse stock split of its ordinary shares and a change in the ordinary share/ADS ratio from 500,000:1 to 50:1. This move is intended to rationalize the company's share capital and administration without affecting the number of American Depositary Shares (ADSs) held, shareholders' percentage ownership, or their rights. The proposal also involves creating new E deferred shares with negligible rights, with the changes being inter-conditional and effective on June 18, 2026, if approved.

Biodexa Pharmaceuticals PLC-ADR ( NASDAQ:BDRX ) saw its stock fall 3.67% to $10.50 during after-hours trading on Thursday. Check out the current price of BDRX stock here.

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

August ...

June ...

Shares of Intuit Inc. INTU rose sharply in today's pre-market after the company reported stronger-than-expected third-quarter financial results and raised its full-year guidance. Intuit reported third-quarter revenue of $7.75 billion, beating analyst estimates of $7.56 billion, according to ...